Acton, Mass. — Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and proprietary data management system Omnipod Discover in Spain, the company’s newest European market.
Spain is the 26th country where Insulet sells Omnipod and the 20th country where Omnipod 5 is available.
“We’re thrilled to introduce Omnipod 5 with Omnipod Discover to Spain—an important and dynamic market where we see a meaningful opportunity to support people with diabetes and the healthcare professionals who care for them,” said Pat Crannell, Insulet Senior Vice President and International General Manager. “Our continued international expansion—including the launch of Omnipod 5 in 15 countries over the last 18 months—reflects the strength of our global growth strategy and passion of our teams. Every new market brings us closer to a world where diabetes demands less.”
Spain is home to more than 4.6 million adults with diabetes, including an estimated 189,000 people with type 1 diabetes and more than 18,500 children and adolescents ages 0 to 19 with the condition.
“Insulet understands that many people living with type 1 diabetes in Spain want tools that are simple and more intuitive, helping them feel safer and more confident. That is why the arrival of Omnipod 5 and Omnipod Discover are important steps towards easing the day-to-day demands of diabetes management while improving the quality of life for individuals and their families,” said Dr. Rafael Bravo, specialist in Endocrinology and Vice President for Global Medical Affairs at Insulet.
Omnipod 5 is a tubeless automated insulin delivery system designed to help simplify diabetes management by automatically adjusting insulin every five minutes to help improve glycemic outcomes, including better time in range and reduced HbA1c, without the need for multiple daily injections. The waterproof, discreet and wearable Pod communicates with a sensor and proactively corrects for highs and helps protect against lows, day and night.
In Spain, Omnipod 5 is indicated for people aged 2 years and older with type 1 diabetes and is compatible with the Abbott FreeStyle Libre 2 Plus sensor and Dexcom G7 sensor.
Insulet said it is working with health authorities, evaluation bodies and Spain’s autonomous communities to support progressive and equitable access to diabetes-management technologies. The company said its goal is to make Omnipod 5 and Omnipod Discover available to people with diabetes who may benefit from the technologies in compliance with regulatory and reimbursement requirements.
Insulet is also launching Omnipod Discover in Spain. The web-based retrospective data analytics and reporting platform is designed for Omnipod 5 users, caregivers and healthcare providers.
Omnipod Discover turns diabetes data into clear, actionable insights that can help inform therapy discussions and support more personalized care. The platform is designed to help users and healthcare providers engage with Omnipod 5 data by highlighting relevant trends and creating easy-to-understand reports to support diabetes management.
